Related Experiment Video

Updated: May 23, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Diffuse metastases of lung adenocarcinoma with EGFR mutation

Kei Kunimasa1, Gen Masuda, Naoki Watanabe

  • 1Department of Respiratory Medicine, Kurashiki Central Hospital, Japan. kk11900@kchnet.or.jp

Internal Medicine (Tokyo, Japan)
|March 28, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Experiment Videos

Last Updated: May 23, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Articles linked to this work by shared authors, journal, and citation graph.

Successful management of fistulous empyema caused by Mycobacterium avium complex in an advanced-age patient: A case report.

Respiratory medicine case reports·2026

First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review.

Internal medicine (Tokyo, Japan)·2026

Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study.

Biomarker research·2026

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

JTO clinical and research reports·2026

Delayed Tumor Shrinkage Beyond Progressive Disease in Small-Cell Lung Cancer Receiving Immunochemotherapy: A Case Report.

Thoracic cancer·2026

Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.

Cancer research communications·2026

Life Course Immunization in Japan: A Practice-Oriented Framework for Internal Medicine.

Internal medicine (Tokyo, Japan)·2026

Contemporary Guideline Perspectives on Methotrexate and Biologic/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Internal medicine (Tokyo, Japan)·2026

Esophageal cancer-associated thoracic central venous obstruction type 2 which occurred during chemoradiotherapy.

Internal medicine (Tokyo, Japan)·2026

Gastrointestinal Diseases and Sarcopenia.

Internal medicine (Tokyo, Japan)·2026

Chronic Kidney Disease with Sjögren's Syndrome and Hyperthyroidism: Discrepant Creatinine- and Cystatin C-Based eGFR.

Internal medicine (Tokyo, Japan)·2026

Coexistent IgG4-Related Sclerosing Cholecystitis and Xanthogranulomatous Cholecystitis in the Gallbladder: A Case Report.

Internal medicine (Tokyo, Japan)·2026

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.

Cancer·2026

Predictive Value of Preoperative Chest Computed Tomography-Measured Diaphragm Thickness Combined With Pulmonary Function for Postoperative Pulmonary Complications After Anatomic Lung Resection in Elderly Patients With Clinical Stage I Non-Small Cell Lung Cancer.

The American surgeon·2026

Integrated Bulk and Single-Cell Transcriptomic Analyses Identify a Five-Gene Signature Associated With Prognosis and the Tumor Microenvironment in Epstein-Barr Virus-Associated Gastric Cancer.

Genetics research·2026

Brain Network Convergence of Abnormal Gray Matter and Functional Activity of Pathological Dissociative Symptoms.

Psychiatry and clinical neurosciences·2026

SHMT2: a Metabolic and Immune Biomarker of Aggressive Lung Adenocarcinoma.

Journal of visualized experiments : JoVE·2026

Time-dependent predictors of seizure outcome in grade 1-2 glioma-related epilepsy.

Epilepsia·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us